Innoviva, Inc. (FRA:HVE)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.35B +29.3% |
| Revenue (ttm) | 364.86M +13.7% |
| Net Income | 437.42M |
| EPS | 4.94 |
| Shares Out | n/a |
| PE Ratio | 3.09 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 18.20 |
| Previous Close | 18.20 |
| Day's Range | 18.20 - 18.20 |
| 52-Week Range | 14.20 - 21.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About Innoviva
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use ... [Read more]
Financial Performance
In 2025, Innoviva's revenue was $411.33 million, an increase of 14.67% compared to the previous year's $358.71 million. Earnings were $271.17 million, an increase of 1059.22%.
Financial numbers in USD Financial StatementsNews
Innoviva to Participate in Upcoming Investor Conferences
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva management to meet with BTIG
Biotech Analyst Harrison holds a Meeting with Management in San Francisco on May 18 hosted by BTIG.
Innoviva management to meet with BTIG
Biotech Analyst Harrison holds a Meeting with Management in Texas on May 20 hosted by BTIG.
Innoviva price target raised to $42 from $35 at BTIG
BTIG raised the firm’s price target on Innoviva (INVA) to $42 from $35 and keeps a Buy rating on the shares after its Q1 results. Royalty revenue from Breo and…
Innoviva reports Q1 EPS $2.22 vs (74c) last year
Reports Q1 revenue $98M, consensus $101.56M. “We delivered a strong start to 2026, driven by the resilience of our royalty portfolio, continued excellent commercial progress at IST, and meaningful val...
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva Earnings release: Q1 2026
Innoviva released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Innoviva Quarterly report: Q1 2026
Innoviva has published its Q1 2026 quarterly earnings report on May 6, 2026.
Innoviva Proxy statement: Proxy filing
Innoviva filed a proxy statement on March 24, 2026, providing details for shareholder voting and corporate governance matters.
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation's 2026 Antimicrobial Resistance Benchmark Report
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc., today announced that its infectious disease therapeutic portfolio earned a strong performance rating of...
3 Small-Cap ‘Strong Buy’ Stocks with Big Upside in 2026, According to Analysts
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Diversified Energy Company ($DEC), Atricure ($ATRC), and Innoviva ($INVA) as companies wi...
Innoviva Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Innoviva highlighted robust growth across its royalty, specialty therapeutics, and strategic healthcare asset segments, with strong cash flow and multiple catalysts expected in 2026. Key products like GIAPREZA, XACDURO, ZEVTERA, and NUZOLVENCE are driving sales, while Armata and other assets offer significant upside.
Innoviva price target raised to $32 from $31 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Innoviva (INVA) to $32 from $31 and keeps an Overweight rating on the shares. Q4 revenue of $114.6M exceeded…
Innoviva reports Q4 EPS $1.94 vs. 26c last year
Reports Q4 revenue $114.6M, consensus $102.6M. The company said, “2025 marked an excellent year for Innoviva (INVA), demonstrating strength across all areas of our business, with 15% revenue growth to...
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and i...
Innoviva Earnings release: Q4 2025
Innoviva released its Q4 2025 earnings on February 25, 2026, summarizing the period's financial results.
Innoviva Annual report: Q4 2025
Innoviva has published its Q4 2025 annual report on February 25, 2026.
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious ...
Innoviva initiated with a Buy at BTIG
BTIG initiated coverage of Innoviva (INVA) with a Buy rating and $35 price target Innoviva is positioned to capture more than $1.2B in royalties through 2030 from two COPD/asthma inhaled…
Innoviva price target raised to $46 from $45 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Innoviva (INVA) to $46 from $45 and keeps a Buy rating on the shares. The firm says zoliflodacin was approved on schedule.
Innoviva Specialty Therapeutics announces FDA approval of Nuzolvence
Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced that the U.S. FDA has approved Nuzolvence for oral suspension, a first-in-class, single-dose oral medication for the treatme...
U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents
WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ: INVA), today announced that the U.S. Food and Drug Administration (FDA) has approved NUZOLVENC...
US FDA approves Innoviva's oral antibiotic for common sexually transmitted infections
The U.S. Food and Drug Administration has approved Innoviva's oral antibiotic for common sexually transmitted infection, offering patients a pill instead of the injection that is currently the only re...
Innoviva Slides: Corporate presentation
Innoviva has posted slides in relation to its latest quarterly earnings report, which was published on December 12, 2025.
Innoviva announces Lancet publication of ‘positive’ Zoliflodacin Phase 3 data
Innoviva (INVA) Specialty Therapeutics “announced the publication of positive results from a pivotal Phase 3 trial evaluating its investigational single-dose, oral antibiotic zoliflodacin for the trea...